- 2024.08.26
Press Releases
2024.11.14
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027, based on $184.4 million in cash and […]
2024.11.06
ROCKVILLE, MD, November 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company’s permanent Chief Executive Officer (“CEO”) effective November 1, 2024. Dr. Fu […]
2024.10.31
ROCKVILLE, MD, October 31, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. […]
I-Mab was established in June 2016
I-Mab completed Series A financing, raising $58 million
Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing
I-Mab successfully raised $227 million in Series C Financing
I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company
I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab
I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium
I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou
I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China
I-Mab signed agreement to divest its assets and business operations in China, bringing a greater focus on the U.S. and ex-China markets